Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors

Published:2021-03-24 Issue:3 Volume:4 Page:e211136
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Park Hyo Jung¹,Kim Kyung Won¹,Won Sang Eun¹,Yoon Shinkyo²,Chae Young Kwang³,Tirumani Sree Harsha⁴,Ramaiya Nikhil H.⁴

Affiliation:

1. Asan Image Metrics, Asan Medical Center, Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Seoul, Republic of Korea

2. Asan Medical Center, Department of Oncology, University of Ulsan College of Medicine, Seoul, Republic of Korea

3. Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University, Chicago, Illinois

4. University Hospitals Cleveland Medical Center, Department of Radiology, Case Western Reserve University, Cleveland, Ohio

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2777859/park_2021_oi_210058_1616042439.44316.pdf

Reference44 articles.

1. Novel patterns of response under immunotherapy.;Borcoman;Ann Oncol,2019

2. Hyperprogressive disease: recognizing a novel pattern to improve patient management.;Champiat;Nat Rev Clin Oncol,2018

3. Impact of pseudoprogression and treatment beyond progression on outcome in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.;Won;Oncoimmunology,2020

4. Hyperprogression as a distinct outcome after immunotherapy.;Fuentes-Antrás;Cancer Treat Rev,2018

5. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1.;Champiat;Clin Cancer Res,2017

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The NSCLC immunotherapy response predicted by tumor-infiltrating T cells via a non-invasive radiomic approach;Frontiers in Immunology;2024-09-09

2. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors;Clinical and Translational Oncology;2024-09-03

3. First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature Review;2024-08-06

4. Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy;Investigative Radiology;2024-07-17

5. Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies;Journal for ImmunoTherapy of Cancer;2024-06